This medication is combination of hormones, prescribed for infertility in women. It is generally used as part of an Assisted Reproduction Technology (ART) program. It is a purified preparation of gonadotropins extracted from the urine of postmenopausal women. It stimulates the ovaries to produce eggs.
This medication is not advisable to pregnant & breastfeeding women. Ovarian cysts or enlarged ovaries (not due to polycystic ovarian syndrome), uncontrolled thyroid and adrenal dysfunction, organic intracranial lesions (e.g. pituitary tumours), abnormal genital bleeding of unknown cause, presence of other causes of infertility other than anovulation (unless they are candidates of in vitro-fertilization), hormone sensitive tumours e.g. breast, uterus, prostate, ovaries or testes. Primary ovarian failure, malformation of sexual organs or fibroid tumours of the uterus incompatible with pregnancy, structural abnormalities such as tubal occlusion (unless super ovulation is to be induced), ovarian dysgenesis, absence of uterus or premature menopause.
IM/SC- Female Infertility- Daily dose providing 75-150u FSH. Adjust dose gradually till adequate response. Once reached, stop menotropin and induce ovulation with chorionic gonadotrophin 1-2 days later. In menstruating patients, start treatment within the 1st 7 days of the menstrual cycle; may repeat cycle at least twice more if needed.
It is usually administered as an injection under the skin (subcutaneously) by a health care provider.
• It may cause dizziness. Do not drive a car, operate machinery, or do anything else that could be dangerous until you know how you react to this medication.
• Monitor ovarian activity and measure urinary estrogen at regular intervals, until stimulation occurs.
• Discontinue this treatment and withhold human chorionic gonadotrophin if urinary estrogen levels >540 nmol/24 hours, or if plasma 17 β-estradiol levels >3000 pmol/l, or if there is any sharp rise in values.
• Refrain from sexual intercourse or use barrier contraception methods for at least 4 days and pelvic examinations to be avoided or carried out with care.
• Caution should be exercised in patients with history liver, kidney disease, any allergy, and who are taking other medications.
Fast heart rate and vascular complications.
• Central Nervous System: Headache, dizziness, malaise and migraine.
• Skin: Flushing and body rashes.
• Gastrointestinal: Nausea, abdominal pain, abdominal fullness, abdominal cramping, enlarged abdomen, vomiting, diarrhea, constipation and bloating.
• Genitourinary: Ovarian hyper stimulation syndrome (OHSS), vaginal bleeding, ovarian enlargement, pain following retrieval of eggs for in vitro fertilization, pelvic cramps, uterine spasm, breast tenderness, hot flashes, menstrual disorder, pelvic disorder, pelvic pain and pregnancy outside the uterine cavity.
• Hypersensitivity: Sensitivity including febrile reactions, flu-like symptoms (eg, chills, fever, musculoskeletal aches, joint pains and nausea.
• Local: Injection site edema or reaction, irritation, pain, rash and swelling.
• Musculoskeletal: Back pain.
• Respiratory: Respiratory disorder, increased cough, difficulty in breathing, pulmonary and respiratory complications and fast breathing.
• Miscellaneous: Elevated estradiol, infection and presence of blood in the peritoneal cavity.
Do not reuse needles, syringes, or other materials. Dispose properly after use.
Injection: Refrigerate or store it at room temperature, 37 to 77 degrees F (3 to 25 degrees C). Store it in airtight container and keep away from children.
Subscribe to our Free Newsletters!